Despite initial success in T-cell lymphoma and multiple myeloma, most clinical trials for several solid cancers, including ovarian, NSCLC, colorectal and prostate, indicated that HDAC inhibitor monotherapy is not an effective treatment [153,154,155,156]. This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.